Here's the screener: "Primary therapy must consist of surgical resection with the intent for a gross or near total resection of the contrast-enhancing tumor mass, followed by conventional external beam radiation therapy and concurrent Temodar chemotherapy. Patients having a biopsy only will be excluded."
The point is DCVax-L did not allow Biopsy only patients, while multiple ECA trials DID allow Biopsy only patients.
Market Data 
Markets 
AI
